About Cyclerion
Cyclerion is a company based in Cambridge (United States) founded in 2018.. The company has 1 employees as of December 31, 2024. Cyclerion offers products and services including Biofeedback Delivery Device and TRD Therapy. Cyclerion operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 1 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cyclerion Therapeutics, Inc.
-
Annual Revenue
$2 M0as on Dec 31, 2024
-
Net Profit
$-3.06 M85.45as on Dec 31, 2024
-
EBITDA
$-3.63 M62.39as on Dec 31, 2024
-
Latest Funding Round
$18.03 M (USD), Post-IPO
Jun 04, 2021
-
Investors
Alzheimer’s Association
& 7 more
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cyclerion
Cyclerion is a publicly listed company on the NASDAQ with ticker symbol CYCN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cyclerion
Cyclerion offers a comprehensive portfolio of products and services, including Biofeedback Delivery Device and TRD Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers anesthetics for treating depression via personalized biofeedback.
Innovative therapy targeting treatment-resistant depression through technology.
Unlock access to complete
Funding Insights of Cyclerion
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $18.0M
-
First Round
First Round
(17 Apr 2019)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Post-IPO - Cyclerion | Valuation |
investors |
|
| Aug, 2020 | Amount | Grant - Cyclerion | Valuation |
investors |
|
| Aug, 2020 | Amount | Post-IPO - Cyclerion | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cyclerion
Cyclerion has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Alzheimer’s Association, EcoR1 and Slate Path Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward North American opportunities.
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cyclerion
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cyclerion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cyclerion Comparisons
Competitors of Cyclerion
Cyclerion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for sickle cell disease treatment.
|
|
| domain | founded_year | HQ Location |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| domain | founded_year | HQ Location |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cyclerion
Frequently Asked Questions about Cyclerion
When was Cyclerion founded?
Cyclerion was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Cyclerion located?
Cyclerion is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
How many employees does Cyclerion have?
As of Dec 31, 2024, the latest employee count at Cyclerion is 1.
What is the annual revenue of Cyclerion?
Annual revenue of Cyclerion is $2M as on Dec 31, 2024.
What does Cyclerion do?
Cyclerion is involved in developing therapies for treating sickle cell disease (SCD) and diabetic nephropathy. They are focussed on the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Their lead candidate, Olinciguat, which is a vascular guanylate cyclase agonist. The candidate is in phase II clinical trial. They have granted Orphan Drug Designation for SCD by the U.S. Food and Drug Administration.
Who are the top competitors of Cyclerion?
Cyclerion's top competitors include GBT, Editas Medicine and Kedrion.
What products or services does Cyclerion offer?
Cyclerion offers Biofeedback Delivery Device and TRD Therapy.
Is Cyclerion publicly traded?
Yes, Cyclerion is publicly traded on NASDAQ under the ticker symbol CYCN.
Who are Cyclerion's investors?
Cyclerion has 8 investors. Key investors include Alzheimer’s Association, EcoR1, Slate Path Capital, Invus, and Peter Hecht.
What is Cyclerion's ticker symbol?
The ticker symbol of Cyclerion is CYCN on NASDAQ.